School of Natural Sciences, Linnaeus University, Kalmar, Sweden.
Transl Psychiatry. 2012 Mar 13;2(3):e91. doi: 10.1038/tp.2012.19.
Autism spectrum disorders (ASD) are classified as neurological developmental disorders. Several studies have been carried out to find a candidate biomarker linked to the development of these disorders, but up to date no reliable biomarker is available. Mass spectrometry techniques have been used for protein profiling of blood plasma of children with such disorders in order to identify proteins/peptides that may be used as biomarkers for detection of the disorders. Three differentially expressed peptides with mass-charge (m/z) values of 2020 ± 1, 1864 ± 1 and 1978 ± 1 Da in the heparin plasma of children with ASD that were significantly changed as compared with the peptide pattern of the non-ASD control group are reported here. This novel set of biomarkers allows for a reliable blood-based diagnostic tool that may be used in diagnosis and potentially, in prognosis of ASD.
自闭症谱系障碍（ASD）被归类为神经发育障碍。已经进行了几项研究，以寻找与这些疾病发展相关的候选生物标志物，但迄今为止尚无可靠的生物标志物。质谱技术已被用于对患有此类疾病的儿童的血浆进行蛋白质谱分析，以鉴定可能用作疾病检测生物标志物的蛋白质/肽。与非 ASD 对照组的肽图谱相比，在此报道了 ASD 儿童肝素血浆中质量电荷（m/z）值为 2020 ± 1、1864 ± 1 和 1978 ± 1 Da 的三个差异表达肽。这组新的生物标志物可提供可靠的基于血液的诊断工具，可用于 ASD 的诊断和潜在的预后。
